Entwicklungen und Perspektiven radioablativer Verfahren
Authors:
- 19 October 2007
- journal article
- review article
- Published by Springer Nature in Der Radiologe
- Vol. 47 (12) , 1083-1088
Abstract
Die viel versprechenden Ergebnisse der Radioembolisation beim hepatozellulären Karzinom und hepatischen Metastasen des kolorektalen Karzinoms können als Hinweis darauf gewertet werden, dass dieses Therapieverfahren auch beim hepatisch metastasierten Mammakarzinom und bei neuroendokrinen Tumoren erfolgreich sein könnten. Die Kombination von 90Yttrium-Mikrosphären mit strahlensensibilisierenden Substanzen oder auch Wachstumsinhibitoren bietet weitere Möglichkeiten, die Radioembolisation im Verbund mit modernen chemotherapeutischen Konzepten zu testen. Weiterer Bedarf an randomisierten Studien besteht beim hepatozellulären Karzinom für den Vergleich der 90Yttrium-Radioembolisation mit der transarteriellen Chemoembolisation, Embolisation ohne Chemotherapeutikum, Applikation von „drug-eluting beads“ und rein supportiver Behandlung. Ein weiteres potenzielles Forschungsgebiet ist neben der Anwendung der Radioembolisation bei extrahepatischen Tumoren die Ermittlung der Lebensqualität in randomisierten Studien im Vergleich zu systemischen Chemotherapien mit oder ohne perkutane Bestrahlungstherapien. The encouraging preliminary results of radioembolization therapy in hepatocellular carcinoma and liver metastases from colorectal cancer have suggested that this mode of therapy could also be successful in breast and neuroendocrine metastases from colorectal cancer. 90Yttrium microspheres in combination with radiosensitizing agents and growth factor inhibitors present opportunities to evaluate its application in combinatorial treatment paradigms with modern chemotherapy regimens. Other randomized trials are needed in hepatocellular carcinoma, to compare radioembolization with 90yttrium against transarterial chemoembolization, bland embolization, drug-eluting beads, and best supportive care. A further potential research area besides the application of radioembolization for extrahepatic tumors is the determination of quality of life in randomized studies comparing radioembolization with systemic chemotherapy regimens with or without percutaneous radiation therapies.Keywords
This publication has 37 references indexed in Scilit:
- Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II studyBMC Cancer, 2007
- Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200Journal of Clinical Oncology, 2007
- The concurrent chemoradiation paradigm—general principlesNature Clinical Practice Oncology, 2007
- Yttrium-90 microspheres (TheraSphere®) treatment of unresectable hepatocellular carcinoma: Downstaging to resection, RFA and bridge to transplantationJournal of Surgical Oncology, 2006
- SELECTIVE INTERNAL RADIATION THERAPY WITH 90Y MICROSPHERES FOR COLORECTAL LIVER METASTASES: SINGLE‐CENTRE EXPERIENCE WITH 100 PATIENTSAnz Journal of Surgery, 2006
- Management of Hepatocellular Carcinoma *Hepatology, 2005
- FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR StudyJournal of Clinical Oncology, 2004
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancerCancer Treatment Reviews, 2000
- Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institutionHepatology, 1998